Pegtibatinase is a recombinant enzyme commercialized by Travere Therapeutics, with a leading Phase II program in Homocystinuria. According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Pegtibatinase’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Pegtibatinase is expected to reach an annual total of $17 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Pegtibatinase (OT-58) is under development for the treatment of homocystinuria. It is administrated through subcutaneous route as a solution. The drug candidate is an enzyme replacement therapy (ERT). It is a pegylated version of truncated recombinant human cystathionine beta-synthase (CBS) enzyme.
Travere Therapeutics Overview
Travere Therapeutics, formerly Retrophin, is a biopharmaceutical company that discovers, develops, acquires, and markets drugs for the treatment of rare diseases. The company’s products include thiola, chenodal and cholbam. It develops drugs for therapies to people living with liver, rare kidney and metabolic diseases. Travere Therapeutics pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. Travere Therapeutics is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$212 million for the fiscal year ended December 2022 (FY2022), a decrease of 6.8% over FY2021. The operating loss of the company was US$274.1 million in FY2022, compared to an operating loss of US$161.8 million in FY2021. The net loss of the company was US$278.5 million in FY2022, compared to a net loss of US$180.1 million in FY2021. The company reported revenues of US$57 million for the first quarter ended March 2023, an increase of 2% over the previous quarter.
For a complete picture of Pegtibatinase’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.